Inhibition of activator protein 1 activity and neoplastic transformation by aspirin

Zigang Dong, Chuanshu Huang, Rhoderick E Brown, Wei-Ya Ma

Research output: Contribution to journalArticlepeer-review

166 Scopus citations

Abstract

Aspirin, along with its analgesic-antipyretic uses, is now also being considered for prevention of cardiovascular disease, cancer, and treatment of human immunodeficiency virus infection. Although many of aspirin's pharmacological actions are related to its ability to inhibit prostaglandin biosynthesis, some of its beneficial therapeutic effects are not completely understood. Transcription factor activator protein 1 (AP-1) is critical for the induction of neoplastic transformation and induction of multiple genes involved in inflammation and infection. We have used the JB6 mouse epidermal cell lines, a system that has been used extensively as an in vitro model for the study of tumor promotion and antitumor promotion, to study the anti- carcinogenesis effect of aspirin at the molecular level. Aspirin and aspirin like salicylates inhibited the activation of AP-1 in the same dose range as seen for the inhibition of tumor promoter-induced transformation. The inhibition of AP-1 and tumor promoter-induced transformation in JB6 cells occurs through a prostaglandin independent- and an Erk1- or Erk2-independent pathway. The mechanism of AP-1 and transformation inhibition in this cell culture model may involve the elevation of H+ concentration. The inhibition effects on the activation of AP-1 activity by aspirin and aspirin-like salicylates may further explain the anti-carcinogenesis mechanism of action of these drugs.

Original languageEnglish (US)
Pages (from-to)9962-9970
Number of pages9
JournalJournal of Biological Chemistry
Volume272
Issue number15
DOIs
StatePublished - Apr 11 1997

Fingerprint Dive into the research topics of 'Inhibition of activator protein 1 activity and neoplastic transformation by aspirin'. Together they form a unique fingerprint.

Cite this